Place of antazoline in modern pharmacotherapy Review article
Article Sidebar
Main Article Content
Abstract
Antazoline belongs to the first generation of antyhistamines, that is, drugs which block the H1 receptor. It presents a number of properties that can be used clinically, including antiarrhytmic activity. Its cardiological use was quite popular years ago. However, with time, due to a large number of side effects, it gave way to newer substances. Currently in Poland, many antiarrhytmic drugs have been withdrawn from the market (ibutilide, flecainide), do not work properly (dronedarone), or the barrier to their use remains the price and availability (vernakalant) or side effects (amiodarone). Antazoline is inexpensive, widely available, safe to use and a growing amount of evidence shows that it is also quite effective in certain subpopulations of patients.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
2. Woodward J.K.: Pharmacology and toxicology of nonclassical antihistamines. Cutis 1988; 42: 5-9.
3. Tarchalska-Kryńska B.: Leki przeciwhistaminowe H1 stosowane w terapii chorób alergicznych. Nowa Medycyna 1999; 1: 14-18.
4. Mutschler E., Geisslinger G., Kroemer H. et al.: Farmakologia i Toksykologia. Urban i Partner, Wrocław 2004: 564.
5. Urząd Rejestracji Produktów Leczniczych i Preparatów Biobójczych, http://www.urpl.gov.pl.
6. Camm A., Kirchof P., Lip G. et al.: Kardiologia Polska 2010; 68(supl. VII): 487-566.
7. Kline S.R., Dreifus L.S., Watanabe Y. et al.: Evaluation of the antiarrhythmic properties of antazoline. A preliminary study. Am. J. Cardiol. 1962; 9: 564-567.
8. Tarchalska-Kryńska B.: Nowe generacje leków przeciwhistaminowych stosowanych w terapii chorób alergicznych. Alergia Astma Immunologia 1997; 2: 3-8.
9. Pasini U., Carvalhofilho E.T., Giuliano H. et al.: The use of antazoline in the treatment of cardiac arrhythmias. Clinical study. Arq. Bras. Cardiol. 1964: 17: 303-312.
10. Shah S., Vaidya C., Doshi H. et al.: Antazoline in the treatment of cardiac arrhytmias. Postgrad. Med. J. 1972; 48(559): 304-307.
11. Reynolds E.W., Baird W.M., Clifford M.E. et al.: A clinical trial of antazoline in the treatment of arrhythias. Am. J. Cardiol. 1964; 14: 513-521.
12. Piotrowski R., Kryński T., Baran J. et al.: Antazoline for rapid termination of atrial fibrillation during ablation of accessory pathways. Cardiol. J. 2014; 21(3): 299-303.
13. Balsam P., Koźluk E., Peller M. et al.: Antazoline for termination of atrial fibrillation during the procedure of pulmonary veins isolation. Adv. Med. Sci. 2015; 60(2): 231-235.